Related Experiment Videos
[Do inhaled corticosteroids reduce mortality in chronic obstructive pulmonary disease?]
Pierre-Olivier Bridevaux1, Philippe Leuenberger
1Service de pneumologie, CHUV,1011 Lausanne. Pierre-Olivier.Bridevaux@chuv.ch
Revue Medicale Suisse
|December 17, 2005
Summary
High doses of inhaled corticosteroids do not reduce mortality in COPD patients. Methodological biases in observational studies may incorrectly suggest survival benefits, but recent research controlling for these issues finds no mortality reduction.
Area of Science:
- Pulmonary Medicine
- Pharmacoepidemiology
Context:
- High-dose inhaled corticosteroids (ICS) are frequently prescribed to COPD patients in Switzerland.
- Observational studies suggest ICS reduce mortality, but randomized controlled trials (RCTs) show no benefit.
Purpose:
- To critically review methodological biases in observational studies of ICS in COPD.
- To evaluate the effect of ICS on mortality in COPD patients, accounting for biases.
Summary:
- Observational studies are prone to immortal time bias and inadequate time-dependent analysis, underestimating mortality risk and falsely suggesting survival benefits.
- Recent pharmaco-epidemiological studies controlling for these biases found no reduction in COPD mortality with regular inhaled steroid use.
Impact:
- Highlights the need for rigorous methodology in pharmaco-epidemiological research.
- Informs clinical practice regarding the use of inhaled corticosteroids in COPD management.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...